Armin Schulz
Born in Mönchengladbach, he studied business administration in the Netherlands. In the course of his studies he came into contact with the stock exchange for the first time. He has more than 25 years of experience in stock market business.
After graduating, he worked as an IT consultant for a listed company before becoming self-employed, during which time he worked for various DAX-listed companies and a large Swiss insurance company, among others.
Since 2009, he has been exclusively involved in the capital markets, where he was able to gain experience as a day and swing trader, in investor relations and at board level. He was able to live out his passion for numbers in the controlling department of a securities trading house.
For him, fundamental analysis paired with the correct reading of the price action of a market provides the basis for successful trading.
Commented by Armin Schulz
Commented by Armin Schulz on October 13th, 2025 | 07:10 CEST
Why smart investors should be looking at Gerresheimer, Desert Gold, and Puma NOW!
The true potential of a portfolio is revealed not in calm markets, but in turbulent ones. While the masses are driven by price fluctuations, savvy investors recognize opportunities in companies that have recently underperformed. The key lies in a targeted analysis of resilient niche players, commodity experts with unique access, and global consumer brands that are on the verge of a turnaround. This strategic positioning often makes the difference between average and exceptional returns. Three promising candidates that currently embody this profile are Gerresheimer, Desert Gold, and Puma.
Read
Commented by Armin Schulz on October 10th, 2025 | 07:15 CEST
From food waste to profit: How Nestlé, Planethic Group, and HelloFresh are capitalizing on the latest megatrends
The food industry is currently undergoing what may be the most lucrative revolution in its history. Driven by groundbreaking technologies, from 2D printing for food to the hype surrounding plant-based proteins, and the global drive to curb food waste, entirely new markets are emerging. By keeping an eye on the companies driving these megatrends, you can identify the major growth opportunities of the future at an early stage. Today, we take a close look at the strategies of Nestlé, Planethic Group, and HelloFresh and ask ourselves: Which stocks really have what it takes to succeed?
Read
Commented by Armin Schulz on October 10th, 2025 | 07:00 CEST
Drone boom vs. pilot strike: What you need to know about DroneShield, Volatus Aerospace, and Lufthansa
As the global drone market expands at double-digit growth rates, unprecedented opportunities are emerging above and beyond the clouds. Innovative technologies are driving not only military but also civilian applications into previously untapped economic areas. This high-flying growth stands in sharp contrast to the challenges facing traditional aviation, which is being hit by operational difficulties. Three companies - DroneShield, Volatus Aerospace, and Lufthansa - embody these contrasting realities, highlighting both the lucrative paths of the future and the risks inherent in the sector.
Read
Commented by Armin Schulz on October 9th, 2025 | 07:40 CEST
AI paves the way to the next blockbuster: The current situation at Novo Nordisk, NetraMark Holdings and Evotec
The pharmaceutical industry is at a historic turning point. Artificial intelligence is breaking through the lengthy and costly development cycles that have characterized the sector for decades. This technological quantum leap is revolutionizing drug discovery and promises to transform healthcare from the ground up. The first companies to master this AI revolution will be the biggest winners in a billion-dollar market. We therefore take a look at three companies that are already using AI today: the Danish pharmaceutical giant Novo Nordisk, AI specialist NetraMark Holdings for clinical studies, and the German research service provider Evotec, and analyze their current situation.
Read
Commented by Armin Schulz on October 9th, 2025 | 07:00 CEST
Almonty Industries' Raw material power brings Rheinmetall and Lockheed Martin into a new geopolitical era
Nations around the world are investing record sums in their defense capabilities. This defense boom is driving demand for critical raw materials to unprecedented heights. Suddenly, critical metals such as tungsten are at the center of global politics. They have become strategic commodities, with security of supply directly influencing military strength. This development is creating real momentum for companies covering the entire value chain, from mining to the defense industry to high-tech. Three stocks that perfectly embody this interplay between raw materials, production, and technology are Almonty Industries, Rheinmetall, and Lockheed Martin.
Read
Commented by Armin Schulz on October 8th, 2025 | 07:20 CEST
Gold rush! Your portfolio for the USD 4,000 mark: Barrick Mining, Kobo Resources and Newmont
The magical threshold of USD 4,000 per ounce is within reach. Driven by geopolitical crises, a weak US dollar, and the global wave of de-dollarization, investors are flocking to the safe haven of gold. This historic bull market, fueled by ongoing expectations of interest rate cuts, offers unprecedented momentum. But how can investors directly capitalize on this potential? The key lies in the right producers and explorers, who will benefit maximally from any further price increases. Companies such as Barrick Mining, Kobo Resources and Newmont are now in the spotlight.
Read
Commented by Armin Schulz on October 8th, 2025 | 07:10 CEST
The Uptober Bonus: How to leverage Coinbase, Nakiki, and Riot Platforms for the next price sprint
The perfect interplay of macroeconomic turmoil, institutional capital flows, and seasonal patterns is fueling a spectacular crypto boom. Bitcoin, at the forefront of this frenzy, is climbing to unimaginable heights and pulling the entire sector along with it. It is already a historic trend that Bitcoin tends to rise in October, hence the term "Uptober." In this euphoric market phase, three players are coming into particular focus, each poised to benefit directly from these dominant trends: a leading trading platform, an innovative altcoin protagonist, and an industrial-scale Bitcoin miner. The strategies of Coinbase, Nakiki, and Riot Platforms could be the key to profiting from this unprecedented rally.
Read
Commented by Armin Schulz on October 7th, 2025 | 07:20 CEST
Cancer research with billion-dollar potential: How Bayer, Vidac Pharma, and BioNTech could come into play
The oncology market is booming like no other. Driven by technological quantum leaps and, unfortunately, rising case numbers, cancer treatment is becoming a highly lucrative innovation engine. The sector is growing at double-digit rates every year. Experts predict that the global market volume will break the USD 1 trillion mark within the next decade. No wonder, then, that the race for the next therapeutic breakthroughs in personalized medicines and AI-supported active ingredients is heating up. Investors are focusing not only on established players like Bayer, but also on up-and-coming specialists such as Vidac Pharma and mRNA pioneers like BioNTech.
Read
Commented by Armin Schulz on October 7th, 2025 | 07:05 CEST
Steel, hydrogen, SMRs, renewable energy: How to cover all the megatrends with thyssenkrupp, First Hydrogen and RWE
The global industry is undergoing a radical transformation. Drivers include volatile supply chains, ambitious climate targets, and technological change. This tension is giving rise to new markets and unexpected winners. Some pioneers are already showing how this transformation can be turned into profit. They combine deep structural change with a green hydrogen economy and groundbreaking energy research. Three companies exemplify how this transformation can not only be mastered but also leveraged as an opportunity: thyssenkrupp, First Hydrogen, and RWE.
Read
Commented by Armin Schulz on October 3rd, 2025 | 07:05 CEST
BioNxt Solutions' pharmaceutical revolution: New ways of administering blockbuster drugs
Imagine chemotherapy without severe side effects or a blockbuster drug without needles. What sounds like a pipe dream is now becoming reality thanks to innovative drug delivery systems. They are revolutionizing billion-dollar markets from oncology to obesity therapy and laying the foundation for exponential growth. For investors, this technological breakthrough opens up a unique investment window. BioNxt Solutions is at the forefront of this movement.
Read